Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 79-89

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 8, 2015-08 ,pp. : 658-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of the peginterferon‐α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV‐co‐infected patients with the unfavourable non‐CC IL28B genotypes

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 21, Iss. 3, 2014-03 ,pp. : 178-188

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

By  

Oncology, Vol. 89, Iss. 2, 2015-0 ,pp. : 42-46

Karger

Access to resources Recommend Favorite

Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 5, 2015-05 ,pp. : 501-513

John Wiley & Sons Inc

Access to resources Recommend Favorite